JP2023539871A - グリア芽細胞腫を処置するための方法および組成物 - Google Patents

グリア芽細胞腫を処置するための方法および組成物 Download PDF

Info

Publication number
JP2023539871A
JP2023539871A JP2023513567A JP2023513567A JP2023539871A JP 2023539871 A JP2023539871 A JP 2023539871A JP 2023513567 A JP2023513567 A JP 2023513567A JP 2023513567 A JP2023513567 A JP 2023513567A JP 2023539871 A JP2023539871 A JP 2023539871A
Authority
JP
Japan
Prior art keywords
seq
region
polypeptide
amino acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539871A5 (enExample
Inventor
イボンヌ ユ－シュアン チェン
アンドリュー ジェイ． フー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2023539871A publication Critical patent/JP2023539871A/ja
Publication of JP2023539871A5 publication Critical patent/JP2023539871A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023513567A 2020-08-26 2021-08-25 グリア芽細胞腫を処置するための方法および組成物 Pending JP2023539871A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063070550P 2020-08-26 2020-08-26
US63/070,550 2020-08-26
US202163171187P 2021-04-06 2021-04-06
US63/171,187 2021-04-06
US202163218761P 2021-07-06 2021-07-06
US63/218,761 2021-07-06
PCT/US2021/047604 WO2022046938A1 (en) 2020-08-26 2021-08-25 Methods and compositions for treating glioblastoma

Publications (2)

Publication Number Publication Date
JP2023539871A true JP2023539871A (ja) 2023-09-20
JP2023539871A5 JP2023539871A5 (enExample) 2024-08-27

Family

ID=80352963

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023513567A Pending JP2023539871A (ja) 2020-08-26 2021-08-25 グリア芽細胞腫を処置するための方法および組成物
JP2023513564A Pending JP2023539870A (ja) 2020-08-26 2021-08-25 グリア芽細胞腫を処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023513564A Pending JP2023539870A (ja) 2020-08-26 2021-08-25 グリア芽細胞腫を処置するための方法および組成物

Country Status (6)

Country Link
US (2) US20230364139A1 (enExample)
EP (2) EP4204443A4 (enExample)
JP (2) JP2023539871A (enExample)
CN (2) CN116348482A (enExample)
CA (2) CA3193009A1 (enExample)
WO (2) WO2022046938A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539870A (ja) * 2020-08-26 2023-09-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グリア芽細胞腫を処置するための方法および組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3568466A4 (en) 2017-01-10 2020-07-15 The General Hospital Corporation TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS
US12378297B2 (en) 2017-04-14 2025-08-05 The General Hospital Corporation Chimeric antigen receptor T cells targeting the tumor microenvironment
WO2019157533A1 (en) * 2018-02-12 2019-08-15 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
CN116555204B (zh) * 2023-07-04 2023-09-12 苏州驾玉生物医药有限公司 一种性能提升的突变荧光素酶及其应用
WO2025096603A1 (en) * 2023-10-30 2025-05-08 City Of Hope Targeted chimeric antigen receptor modified t cells for treatment of il13ralpha2 positive malignancies
WO2025193475A1 (en) * 2024-03-14 2025-09-18 The Regents Of The University Of California Enhancing immune cell innate and adaptive responses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513394A (ja) * 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用
JP2019500012A (ja) * 2015-10-30 2019-01-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP2019511244A (ja) * 2016-02-02 2019-04-25 エコール ポリテクニーク フェデラル ド ローザンヌ （エペエフエル） 操作された抗原提示細胞及びそれらの使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884603B2 (en) * 1998-04-03 2005-04-26 The Penn State Research Foundation Nucleic acids encoding IL13 mutants
EP2331566B1 (en) * 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
JP2017537622A (ja) * 2014-12-02 2017-12-21 ロジャー・ウィリアムズ・ホスピタル がんを治療するための方法及び組成物
JP6821688B2 (ja) * 2015-10-09 2021-01-27 ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． キメラ抗原受容体および使用方法
US20180100016A1 (en) * 2016-12-22 2018-04-12 Xiaotong Song Use of car-modified human natural killer cells to treat cancer
BR112019017256A2 (pt) * 2017-02-20 2020-04-14 Dragonfly Therapeutics Inc proteínas de ligação gd2, nkg2d e cd16
CA3095757A1 (en) * 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
JP2023539871A (ja) * 2020-08-26 2023-09-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グリア芽細胞腫を処置するための方法および組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513394A (ja) * 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用
JP2019500012A (ja) * 2015-10-30 2019-01-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP2019511244A (ja) * 2016-02-02 2019-04-25 エコール ポリテクニーク フェデラル ド ローザンヌ （エペエフエル） 操作された抗原提示細胞及びそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BURGER, MICHAEL C. ET AL., FRONTIERS IN IMMUNOLOGY, vol. 10, JPN6025030872, 2019, ISSN: 0005651758 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539870A (ja) * 2020-08-26 2023-09-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グリア芽細胞腫を処置するための方法および組成物

Also Published As

Publication number Publication date
CN116348482A (zh) 2023-06-27
EP4204443A4 (en) 2025-02-26
CN116528889A8 (zh) 2023-10-31
CA3193009A1 (en) 2022-03-03
WO2022046935A3 (en) 2022-04-07
CA3193006A1 (en) 2022-03-03
EP4203990A2 (en) 2023-07-05
WO2022046938A1 (en) 2022-03-03
JP2023539870A (ja) 2023-09-20
CN116528889A (zh) 2023-08-01
US20230322894A1 (en) 2023-10-12
WO2022046935A2 (en) 2022-03-03
US20230364139A1 (en) 2023-11-16
EP4203990A4 (en) 2025-10-01
EP4204443A1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
JP2023539871A (ja) グリア芽細胞腫を処置するための方法および組成物
AU2007241023B2 (en) Methods and compositions for localized secretion of anti-CTLA-4 antibodies
US20210230289A1 (en) Single-chain bispecific chimeric antigen receptors for the treatment of cancer
KR102930430B1 (ko) 항-bcma 키메라 항원 수용체
TW202136287A (zh) 包含il-7變體之雙官能分子
JP7834345B2 (ja) がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物
US20220265847A1 (en) Methods and compositions for treating non-small cell lung cancer
JP2023554097A (ja) 二機能性抗ｐｄ１／ｉｌ－７分子
TW202128775A (zh) PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
JP2022541200A (ja) Ｃｄ３８に特異性を有する抗体及びその使用
KR20240004680A (ko) 키메라 수용체 및 이의 사용 방법
US20250170177A1 (en) Methods and compositions for treating cancer
US20230303648A1 (en) Bifunctional molecules comprising an il-7 variant
JP7820819B2 (ja) がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物
HK40079124A (en) Chimeric antigen receptors and related methods and compositions for the treatment of cancer
TW202346340A (zh) 抗原結合域及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260423